Partial Seizure - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 89 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Partial Seizure - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Partial Seizure - Pipeline Review, H1 2015', provides an overview of the Partial Seizure's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Partial Seizure
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Partial Seizure and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Partial Seizure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Partial Seizure pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Partial Seizure
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Partial Seizure pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Partial Seizure Overview 7
Therapeutics Development 8
Pipeline Products for Partial Seizure - Overview 8
Pipeline Products for Partial Seizure - Comparative Analysis 9
Partial Seizure - Therapeutics under Development by Companies 10
Partial Seizure - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Partial Seizure - Products under Development by Companies 14
Partial Seizure - Companies Involved in Therapeutics Development 15
Catalyst Pharmaceutical Partners, Inc. 15
Eisai Co., Ltd. 16
Marinus Pharmaceuticals, Inc. 17
Novartis AG 18
Pfizer Inc. 19
SciFluor Life Sciences, LLC 20
SK Biopharmaceuticals Co., Ltd. 21
UCB S.A. 22
Partial Seizure - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 29
brivaracetam - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CPP-115 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
everolimus - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ganaxolone - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
lacosamide - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MB-003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
perampanel - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
pregabalin CR - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
selurampanel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SF-0034 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
YKP-3089 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Partial Seizure - Recent Pipeline Updates 55
Partial Seizure - Dormant Projects 75
Partial Seizure - Discontinued Products 76
Partial Seizure - Product Development Milestones 77
Featured News & Press Releases 77
Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting 77
Jan 05, 2015: Phase III Trial Of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint 79
Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy 80
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting 81
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment 81
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S. 82
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 83
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older 84
Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society 85
Jul 15, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Vimpat 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89

List of Tables

Number of Products under Development for Partial Seizure, H1 2015 8
Number of Products under Development for Partial Seizure - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Partial Seizure - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015 15
Partial Seizure - Pipeline by Eisai Co., Ltd., H1 2015 16
Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015 17
Partial Seizure - Pipeline by Novartis AG, H1 2015 18
Partial Seizure - Pipeline by Pfizer Inc., H1 2015 19
Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H1 2015 20
Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 21
Partial Seizure - Pipeline by UCB S.A., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 24
Number of Products by Stage and Mechanism of Action, H1 2015 25
Number of Products by Stage and Route of Administration, H1 2015 27
Number of Products by Stage and Molecule Type, H1 2015 28
Partial Seizure Therapeutics - Recent Pipeline Updates, H1 2015 55
Partial Seizure - Dormant Projects, H1 2015 75
Partial Seizure - Discontinued Products, H1 2015 76